For 125 years, Boehringer Ingelheim has focused on furthing science to benefit the health of patients and their families. One way that we do is through partnerships with other organizations who share our commitmment to the discovery of innovative new therapies that improve health and quality of life.
The Research Institute of Molecular Pathology (IMP), located in Vienna, Austria is a biomedical research center sponsored largely by Boehringer Ingelheim as well as research grants from national and international funding agencies. Sixteen independent research groups conduct curiosity-driven research spanning a broad range of topics, including computational and structural biology, cell and developmental biology, epigenetics, neurobiology, immunology, and disease mechanisms. Our common goal is to uncover fundamental molecular and cellular mechanisms that underlie complex biological phenomena.
Evotec OAI and Evotec Neurosciences have a three year collaboration with Boehringer Ingelheim. The companies aim to jointly identify and develop small molecule therapeutics acting on selected G-Protein Coupled Receptors.
This community-based clinical trial aims to identify novel approaches for the prevention and treatment of cardiovascular diseases. The trial, a collaboration between Boehringer Ingelheim and the Johannes-Gutenberg-University in Mainz, Germany, seeks to identify correlations between cardiovascular risk and gene expression using novel genomic and proteomic technologies.
Boehringer Ingelheim and AbGenomics Corporation have established a collaboration and license agreement providing Boehringer Ingelheim with the worldwide exclusive rights to develop, manufacture and commercialize an AbGenomics Corporation’s therapeutic monoclonal antibody.
Boehringer Ingelheim has committed significant financial support for the University of Connecticut School of Pharmacy. The Boehringer Ingelheim Dosage Forms Laboratory Suite, a state-of-the-art facility is used for teaching and research in the areas of drug formulation, manufacturing, and quality assessment.